1 Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori: eradication therapy in dyspeptic disease. Edinburgh: SIGN; 1997. (SIGN publication no.7). [section 1.1] [annex 1]

2 Scottish Intercollegiate Guidelines Network (SIGN). Helicobacter pylori: eradication therapy in dyspeptic disease. Update. Edinburgh: SIGN; 1999. (SIGN publication no.7). [section 1.1] [annex 1]

3 Jones RH, Lydeard SE, Hobbs FD, Kenkre JE, Williams EI, Jones SJ, et al. Dyspepsia in England and Scotland. Gut 1990;31:401-5.

4 Penston JG, Pounder RE. A survey of dyspepsia in Great Britain. Aliment Pharmacol Ther 1996;10:83-9.

5 Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:20-8.

6 NHS Scotland. Information and Statistics Division. Prescription cost analysis for Scotland. Edinburgh: The Division; 2002.

7 Haycox A, Einarson T, Eggleston A. The health economic impact of upper gastrointestinal symptoms in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:38-47.

8 Talley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995;40:584-9.

9 Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:48-54.

10 Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45:II37-42. [section 1.3.1] [section 2.3] [section 5.4.3]

11 The Proprietary Association of Great Britain. Annual report 2001. UK Market size statistics 1999/2000. London: The Association; 2001. [cited 26 Aug 2002]. Available from url: http://www.pagb.co.uk/src/About_PAGB/Annual_Report_01/section05.htm

12 Krishnan HS, Schaefer M. Evaluation of the impact of pharmacist’s advice giving on the outcomes of self-medication in patients suffering form dyspepsia. Pharm World Sci 2000;22:102-8.

13 Krska J, John DN, Hansford D, Kennedy EJ. Drug utilization evaluation of nonprescription H2-receptor antagonists and alginate-containing preparations for dyspepsia. Br J Clin Pharmacol 2000;49:363-8. [section 2.1] [section 4.1]

14 Hansen JM, Bytzer P, Schaffalitzky De Muckadell OB. Management of dyspeptic patients in primary care. Value of the unaided clinical diagnosis and of dyspepsia subgrouping. Scand J Gastroenterol 1998;33:799-805. [section 2.3] [section 4.1]

15 Bytzer P, Moller Hansen JM, Schaffalitzky De Muckadell OB, Malchow-Moller A. Predicting endoscopic diagnosis in the dyspeptic patient. Scand. J Gastroenterol 1997;32:118-25.

16 Mann J, Holdstock G, Harman M, Machin D, Loehry CA. Scoring System to improve cost effectiveness of open access endoscopy. BMJ 1983; 287:937-40.

17 Holdstock G, Harman M, Machin D, Patel C, Lloyd RS. Prospective testing of a scoring system designed to improve case selection for upper gastrointestinal investigation. Gastroenterology 1986;90:1164-9.

18 American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 1998;114:579-81. [section 2.4] [section 2.4.1] [section 3.2]

19 Department of Health. Referral Guidelines for suspected cancer. London: The Department; 2000. [cited 26 Aug 2002]. Available from url: http://www.dh.gov.uk/assetRoot/04/01/44/21/04014421.pdf [section 2.4] [section 3.2]

20 Christie J, Shepherd NA, Codling BW, Valori RM. Gastric cancer below the age of 55: implications for screening patients with uncomplicated dyspepsia. Gut 1997;41:513-7.

21 Gillen D, McColl KE. Does concern about missing malignancy justify endoscopy in uncomplicated dyspepsia in patients aged less than 55? Am J Gastroenterol 1999;94:75-9.

22 Heaney A, Collins JS, Tham TC, Watson PR, McFarland JR, Bamford KB. A prospective study of the management of the young Helicobacter pylori negative dyspeptic patient-can gastroscopies be saved in clinical practice? Eur J Gastroenterol Hepatol 1998;10:953-6.

23 Williams B, Luckas M, Ellingham JH, Dain A, Wicks AC. Do young patients with dyspepsia need investigation? Lancet 1988;2:1349-51.

24 Byzter P, Schaffalitsky de Muckadell OB. Prediction of major pathologic conditions in dyspeptic patients referred for endoscopy. A prospective validation study of a scoring system. Scand J Gastroenterol 1992;27:987-92.

25 Wallace MB, Durkalski VL, Vaughan J, Palesch YY, Libby ED, Jowell PS et al. Age and alarm symptoms do not predict endoscopic findings among patients with dyspepsia: a multicentre database study. Gut 2001;49:29-34.

26 Breslin NP, Thomson AB, Bailey RJ, Blustein PK, Meddings J, Lalor E, et al. Gastric cancer and other endoscopic diagnoses in patients with benign dyspepsia. Gut 2000;46:93-7.

27 Gilbert FJ, Park KGM, Thompson AM, editors. Scottish Audit of Gastric and Oesophageal Cancer. Report 1997-2000. A prospective audit. Edinburgh: Scottish Executive Health Department; 2002. [cited 25 Nov 2002]. Available from url: http://www.show.scot.nhs.uk/crag/committees/CEPS/reports/0_prelims.pdf

28 Talley NJ, Axon A, Bytzer P, Holtmann G, Lam SK, Van Zanten S. Management of uninvestigated and functional dyspepsia: a Working Party report for the World Congresses of Gastroenterology 1998. Aliment Pharmacol Ther 1999;13:1135-48. [section 2.4.1] [section 3.2]

29 Ofman JJ, Rabeneck L. The effectiveness of endoscopy in the management of dyspepsia: a qualitative systematic review. Am J Med 1999;106:335-46.

30 Shaw PC, van Romunde LK, Griffioen G, Janssens AR, Kreuning J, Lamers CB. Detection of gastric erosions: comparison of biphasic radiography with fiberoptic endoscopy. Radiology 1991;178:63-6.

31 Stevenson GW, Norman G, Frost R, Somers S. Barium meal or endoscopy? A prospective randomised study of patient preference and physician decision making. Clin Radiol 1991;44:317-21.

32 Simpkins KC. What use is barium? Clin Radiol 1988;39:469-73.

33 Royal College of Radiologists. Making the best use of a department of clinical radiology. Guidelines for doctors. 4th ed. London: The College; 1998.

34 The ionising radiation (medical exposure) regulations 2000. London: The Stationery Office; 2000. (Statutory instruments no. 1059). [cited 27 Aug 2002]. Available from url: http://www.hmso.gov.uk/si/si2000/20001059.htm

35 Stevens R, Baxter G. Benefit of Helicobacter pylori eradication in the treatment of ulcer-like dyspepsia in primary care [abstract]. Digestive disease week. AGA (American Gastroenterological Association). Atlanta, 19-23 May 2001. Congress Review en Gastroenterología y Hepatología; 2001. [cited 20 Nov 2002]. Available from url: http://www.congressreview.com/gastro/aga-01/42.htm

36 Hentschel E, Brandstatter G, Dragosics B, Hirschl AM, Nemec H, Schutze K, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993;328:308-12.

37 Axon AT, O’Morain CA, Bardhan KD, Crowe JP, Beattie AD, Thompson RP, et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ 1997;314:565-8.

38 Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. The management of dyspepsia: a systematic review. Health Technol Assess 2000;4. [cited 4 Sep 2002]. Available from url: http://www.hta.nhsweb.nhs.uk/fullmono/mon439.pdf

39 Delaney BC, Innes MA, Deeks J, Wilson S, Cooner MK, Moayyedi P, Oakes R, Hobbs FDR, Forman D. Initial management strategies for dyspepsia (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.

40 Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A, et al. Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care. BMJ 2001;322:898-901.

41 Heaney A, Collins JS , Watson RG , McFarland RJ, Bamford KB, Tham TC. A prospective randomised trial of a “test and treat” policy versus endoscopy based management in young helicobacter pylori positive patients with ulcer-like dyspepsia, referred to a hospital clinic. Gut 1999;45:186-190.

42 Patel P, Khulusi S, Mendall MA, Lloyd R, Jazrawi R, Maxwell JD, et al. Prospective screening of dyspeptic patients by Helicobacter pylori serology. Lancet 1995;346:1315-8.

43 Lassen AT, Pedersen FM, Bytzer P, Schaffalitzky de Muckadell OB. Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial. Lancet 2000;356:455-60. [section 3.1] [section 3.2.1] [section 4.4.1]

44 Jones R, Tait C, Sladen G, Weston-Baker J. A trial of a test-and-treat strategy for Helicobacter pylori positive dyspeptic patients in general practice. Int J Clin Pract 1999;53:413-6.

45 McColl KE, Murray LS, Gillen D, Walker A, Wirz A, Fletcher J, et al. Randomised trial of endoscopy with testing for Helicobacter pylori compared with non-invasive H pylori testing alone in the management of dyspepsia. BMJ 2002;324:999-1002. [section 3.1] [section 4.4.1]

46 McColl KE. Should we eradicate Helicobacter Pylori in non-ulcer dyspepsia? Gut 2001;48:759-61.

47 Pantoflickova D, Blum A L. Should we eradicate Helicobacter pylori in non-ulcer dyspepsia? Gut 2001;48:758-9.

48 Warburton-Timms VJ, Charlett A, Valori RM, Uff JS, Shepherd NA, Barr H, et al. The significance of cagA(+) Helicobacter pylori in reflux oesophagitis. Gut 2001;49:341-6.

49 Weijnen CF, Numans ME, de Wit NJ, Smouth AJ, Moons KG, Verheij TJ, et al. Testing for Helicobacter pylori in dyspeptic patients suspected of peptic ulcer disease in primary care: cross sectional study. BMJ 2001;323:71-5.

50 McDonagh TA, Woodward M, Morrison CE, McMurray JJ, Tunstall-Pedoe H, Lowe GD, et al. Helicobacter pylori infection and coronary heart disease in the North Glasgow MONICA population. Eur Heart J 1997;18:1257-60.

51 British Society of Gastroenterology. Dyspepsia management guidelines. London: The Society; 1996.

52 Scottish Executive Department of Health. Scottish referral guidelines for suspected cancer. Edinburgh: The Department; 2002. [cited 27 Aug 2002]. Available from url: http://www.show.scot.nhs.uk/sehd/cancerinscotland/Documents/Scottish%20Referral%20Guidelines%20for%20Suspected%20Cancer.pdf

53 Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 2002;324:1012-6.

54 Laheij RJ, Severens JL, Van de Lisdonk EH, Verbeek AL, Jansen JB. Randomized controlled trial of omeprazole or endoscopy in patients with persistent dyspepsia: a cost-effectiveness analysis. Aliment Pharmacol Ther 1998;12:1249-56.

55 McNulty CA, Wyatt JI. ACP Best practice no 154. February 1999. Helicobacter pylori. J Clin Pathol 1999;52:338-44.

56 Klein PD, Malaty HM, Martin RF, Graham KS, Genta RM, Graham DY. Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol 1996;9:690-4.

57 El-Nujumi A, Hilditch TE, Williams C, McColl KE. Current or recent proton pump inhibitor therapy markedly impairs the accuracy of the [14C]urea breath test. Eur J Gastroenterol Hepatol 1998;10:759-64.

58 Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996;91:1138-44.

59 Stevens M, Livsey S, Swann RA, Rathbone BJ. Evaluation of sixteen EIAs for the detection of antibodies to Helicobacter pylori. London: Medical Devices Agency; 1997.

60 Roberts AP, Childs SM, Rubin G, de Wit NJ. Tests for Helicobacter pylori infection: a critical appraisal from primary care. Fam Pract 2000;17:S12-20.

61 Laheij RJ, Straatman H, Jansen JB, Verbeek AL. Evaluation of commercially available Helicobacter pylori serology kits: a review. J Clin Microbiol 1998;36:2803-9.

62 Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001;48:287-9. [section 4.2.2] [section 4.3]

63 Oksanen A, Veijola L, Sipponen P, Schauman KO, Rautelin H. Evaluation of Pyloriset Screen, a rapid whole-blood diagnostic test for Helicobacter pylori infection. J Clin Microbiol 1998;36:955-7.

64 Duggan AE, Hardy E, Hawkey CJ. Evaluation of a new Near Patient Test for the detection of Helicobacter pylori. Eur J Gastroenterol Hepatol 1998; 10:133-6.

65 Ishihara S, Kaji T, Kawamura A, Rumi MA, Sato H, Okuyama T, et al. Diagnostic accuracy of a new non-invasive enzyme immunoassay for detecting Helicobacter pylori in stools after eradication therapy. Aliment Pharmacol Ther 2000;14:611-4.

66 Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N, et al. Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. Aliment Pharmacol Ther 2001;15:73-9.

67 Weijnen CF, Hendriks HA, Hoes AW, Verweij WM, Verheij TJ, de Wit NJ. New immunoassay for the detection of Helicobacter pylori infection compared with urease test, 13C breath test and histology: validation in the primary care setting. J Microbiol Methods 2001;46:235-40.

68 Vaira D, Malfertheiner P, Megraud F, Axon AT, Deltenre M, Gasbarrini G. et al. Noninvasive antigen-based assay for assessing Helicobacter pylori eradication: a European multicenter study. The European Helicobacter pylori HpSA Study Group. Am J Gastroenterol 2000;95:925-9. [section 4.4.1] [section 4.4.2]

69 Gisbert JP, Blanco M, Benito LM, Pajares JM. Value of quantitative serology for confirmation of Helicobacter pylori eradication: an 18-month follow-up study. Clin Infect Dis 2000;30:976-80.

70 Lydeard S, Jones R. Factors affecting the decision to consult with dyspepsia: comparison of consulters and non-consulters. J R Coll Gen Pract 1989; 39:495-8.

71 Cheng C. Seeking medical consultation: perceptual and behavioral characteristics distinguishing consulters and nonconsulters with functional dyspepsia. Psychosom Med 2000;62:844-52.

72 Sihvo S, Hemminki E. Self medication and health habits in the management of upper gastrointestinal symptoms. Patient Educ Couns 1999; 37:55-63.

73 Mullan A, Kavanagh P, O’Mahony P, Joy T, Gleeson F, Gibney MJ. Food and nutrient intakes and eating patterns in functional and organic dyspepsia. Eur J Clin Nutr 1994;48:97-105.

74 Lond E, Varmann P, Elshtein N, Josia U, Litvinenko T, Mumma M, et al. Dyspepsia in rural residents of Estonia. Life-style factors, psychoemotional disorders, and familial history of gastrointestinal diseases. Scand J Gastroenterol 1995;30:826-8.

75 Kaess H, Kellermann M, Castro A. Food intolerance in duodenal ulcer patients, non ulcer dyspeptic patients and healthy subjects. A prospective study. Klin Wochenschr 1988;66:208-11.

76 Elta GH, Behler EM, Colturi TJ. Comparison of coffee intake and coffee-induced symptoms in patients with duodenal ulcer, nonulcer dyspepsia, and normal controls. Am J Gastroenterol 1990;85:1339-42.

77 Nandurkar S, Talley NJ, Xia H, Mitchell H, Hazel S, Jones M. Dyspepsia in the community is linked to smoking and aspirin use but not to Helicobacter pylori infection. Arch Intern Med 1998;158:1427-33.

78 Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in the general population: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:29-37.

79 Woodward M, Morrison CE, McColl KE. The prevalence of dyspepsia and use of antisecretory medication in North Glasgow: role of Helicobacter pylori vs. lifestyle factors. Aliment Pharmacol Ther 1999;13:1505-9.

80 Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Smoking, alcohol and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community. Gut 1994;35:619-24.

81 Hamilton J, Guthrie E, Creed F, Thompson D, Tomenson B, Bennett R, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000;119:661-9.

82 Soo S, Moayyedi P, Deeks J, Delaney B, Lewis M, Forman D. Psychological interventions for non-ulcer dyspepsia. (Cochrane Review). In: The Cochrane Library, Issue 3 2002. Oxford: Update Software.

83 Blum AL, Talley NJ, O’Morain C, van Zanten SV, Labenz J, Stolte M, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998;339:1875-81.

84 Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-11.

85 McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-74.

86 Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999;318:833-7.

87 Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. BMJ 2000;321:659-64.

88 Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9.

89 Danesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000;160:1192-8.

90 Moayyedi P, Soo S, Deeks J, Delaney B, Harris A, Innes M, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia (Cochrane Review). In: The Cochrane Library, Issue 3, 2001. Oxford: Update Software.

91 Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-65.

92 Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. Scand J Gastroenterol 1994;29:618-23.

93 Carvalhinhos C, Fidalgo P, Freire A, Matos L. Cisapride compared with ranitidine in the treatment of functional dyspepsia. Eur J Gastroenterol Hepatol 1995;7:411-7.

94 Farup P, Wetterhus M, Osnes M, Ulshagen K. Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997;8:755-9.

95 Meineche-Schmidt V, Talley NJ, Pap A, Kordecki H et al. Impact of functional dyspepsia on quality of life and health care consumption after cessation of antisecretory treatment. Scand J Gastroenterol 1999;6:566-74.

96 Shukla VK, Otten N, Dubé C, Moher D. Use of cisapride in patients with non-ulcer dyspepsia: a meta-analysis of randomized trials. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2000.

97 Finney FS, Kinnersley N, Hughes M, O’Bryan-Tear CG, Lothian J. Meta-Analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998;26:312-20.

98 Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689-96.

99 Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological Interventions for non-ulcer dyspepsia. (Cochrane Review). In the Cochrane Library, Issue 3, 2001. Oxford: Update Software.

100 Psilogenis M, Nazzari M, Ferrari PA. A multicenter double-blind study of sulglycotide versus sucralfate in nonulcer dyspepsia. Int J Clin Pharmacol Ther Toxicol 1990;28:369-74.

101 Gudjonsson H, Oddsson E, Bjornsson S, Gunnlaugsson O, Theodors A, Jonasson TA, et al. Efficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled study. Scand J Gastroenterol 1993; 28:969-72.

102 Misra SP, Dwivedi M, Misra V, Agarwal SK. Sucralfate versus ranitidine in non-ulcer dyspepsia: results of a prospective, randomized, open, controlled trial. Indian J Gastroenterol 1992;11:7-8.

103 Hausken T, Stene-Larsen G, Lange O, Aronsen O, Nerdrum T, Hegbom F, et al. Misoprostol treatment exacerbates abdominal discomfort in patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled, multicentre study. Scand J Gastroenterol 1990;25:1028-33.

104 Jackson JL, O’Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.

105 Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160-5.

106 Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996;31:318-25.

107 Lindell GH, Celebioglu F, Graffner HO. Non-ulcer dyspepsia in the long-term perspective. Eur J Gastroenterol Hepatol. 1995;7:829-33.

108 Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.

109 Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 1998;42:690-5.

110 Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995;109:671-80.

111 Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001;15:1949-58.

112 Sackmann M, Morgner A, Rudolph B, Neubauer A, Thiede C, Schulz H, et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997;113:1087-90.

113 Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999;131:88-95.

114 Delaney B, Moayyedi P, Forman D. Helicobacter pylori infection. In: Clinical evidence. 8th ed. London: BMJ Publishing Group; 2002. p. 453-68.